Ozempic, Fatty Liver, and the MASH Trial Data

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

6 linked public sourcesEditorial, sourcing, and corrections policy

For the broader cluster context, see the semaglutide side effects and safety hub.

Author: HealthRX.com Editorial Team Evidence checked by: the HealthRX.com Editorial Team Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

A Number That Changed the Conversation

A fatty-liver question needs to distinguish liver fat, MASH and the degree of fibrosis. Ozempic and Wegovy contain semaglutide, but a liver-specific trial or indication should be attached to the actual regimen studied.

This guide sits inside the broader Compounded Semaglutide Side Effects and Safety cluster, which is part of the compounded semaglutide pillar guide.

A note on the preparation itself: compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician prescription. It uses the same active ingredient as Wegovy and Ozempic. It is not FDA-approved. The clinical evidence base for the molecule comes from trials of the branded products. The compounded preparation has not been independently tested in randomized trials at the same scale.

The Safety Dataset, Briefly

The pooled STEP analysis describes gastrointestinal events for semaglutide 2.4 mg. It does not establish a uniform serious-event or pancreatitis risk across different populations, and the liraglutide LEADER trial should not be counted as semaglutide evidence.

The Wegovy and Ozempic labels include a boxed warning regarding thyroid C-cell tumors based on rodent data. The prescribing information states that the relevance of the rodent thyroid C-cell tumor findings to humans is unknown. Most prescribers screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 before writing a prescription.

What the First Eight Weeks Actually Feel Like

The nausea rate should not be inferred from a liver-enzyme change. Pooled STEP 1-3 data reported nausea in 43.9% on semaglutide 2.4 mg weekly and 16.1% on placebo. This obesity-program result is not an Ozempic-specific rate or a direct measure of liver benefit.

A change in energy intake can coincide with treatment, but it does not establish the cause of fatigue. Record intake and the symptom timeline for the prescriber rather than assuming that a food change explains every case.

Here's the thing about side effect intensity: it does not predict results. Trial data from both STEP-1 and STEP-3 show that patients with mild GI tolerability and patients with pronounced symptoms both achieved meaningful weight loss. Suffering more does not mean working harder.

The Liver Story, and Why It Matters

This is where the ozempic fatty liver conversation gets genuinely interesting.

The ESSENCE trial studied weekly semaglutide 2.4 mg in biopsy-defined MASH with stage 2 or 3 fibrosis. The FDA approved Wegovy injection for a defined MASH population in 2025. The current label specifies adults with noncirrhotic MASH and moderate-to-advanced fibrosis. This is not a blanket fatty-liver indication for Ozempic or compounded products.

Think of the liver like a sponge that's been soaking in grease for years. Weight loss wrings some of that grease out. But semaglutide may be doing more than just facilitating weight loss; some data suggest direct metabolic effects on hepatic fat processing, independent of the scale number. The clinical conversation about this is still evolving, and "evolving" here is honest, not hedging.

For patients with elevated liver enzymes or a known diagnosis of fatty liver disease, starting semaglutide therapy includes a discussion of potential liver-related benefits alongside the standard risk-benefit calculus. Active liver disease (particularly cirrhosis or severe hepatic impairment) warrants specific clinical evaluation before initiating GLP-1 therapy. Baseline liver enzymes are commonly checked before starting and during ongoing care.

When to Pick Up the Phone

Most patients set their threshold for calling the prescriber too high. Lower it. Vomiting for more than one day, severe upper abdominal pain (especially radiating to the back), signs of dehydration, jaundice, persistent severe headache, or vision changes are reasons to call promptly.

Most GI side effects don't rise to that threshold and can be managed with a dose hold or symptomatic care. But the cost of calling unnecessarily is zero. The cost of waiting too long on something like pancreatitis is not.

The Boring Truth About Tolerability

The four most reliable interventions for GI tolerability are almost disappointingly simple:

Small, slow meals
Lower-fat content during the first two weeks after any dose change
Adequate hydration (more than most people think)
Avoiding very rich or fried foods around dose escalation

Anti-nausea medication is appropriate for some patients and is a routine tool in the prescriber's kit. There's no award for white-knuckling through preventable nausea.

Four Misconceptions That Keep Circulating

"Compounded is basically the same as FDA-approved." It is not. The active ingredient is the same molecule, yes. But compounding pharmacies operate under a different regulatory framework, with different oversight. Compounded preparations are not FDA-approved. That distinction matters, and pretending it doesn't helps no one.

"If I'm not nauseous, it's not working." See above. No reliable evidence supports this. It's a folk belief that persists because it feels intuitive, which is exactly the kind of belief that trial data exist to correct.

"The medication does the entire job." STEP 1 included lifestyle intervention alongside treatment. A comparison of means from separate trials does not isolate the benefit of changing the lifestyle program. Lifestyle is additive. It is not optional for durable outcomes.

"If I stop, I'll just go back to where I started." Partly true, which is important to understand. STEP-4 documented partial regain over the 48 weeks after switching from active drug to placebo at week 20. The chronic biology of weight regulation reasserts itself without pharmacologic support, the same way blood pressure drifts back up when you stop the antihypertensive. This isn't a failure of willpower. It's physiology.

What Actually Predicts Good Outcomes

The clinician relationship matters more than the brand name on the vial. A program that supports honest clinical conversation, responds to side effects with appropriate adjustments, and provides clear follow-up between refills produces better outcomes than one with slick marketing and weak clinical infrastructure. That's an opinion, but it's one backed by watching this space closely for years.

Individual response varies. The trial means describe averages, not individuals. And lifestyle context matters more on therapy than it does at higher baseline intake, because every calorie consumed carries more nutritional weight when total intake is reduced. A patient eating 1,400 calories of processed food and a patient eating 1,400 calories of balanced protein, fiber, and fat are on very different trajectories, even at the same dose.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide Side Effects and Safety cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Are the side effects of compounded semaglutide different from Wegovy or Ozempic?

The liver and gastrointestinal evidence concerns specified products and regimens. The STEP pooled analysis did not compare compounded programs against branded products, so matching adverse-event rates cannot be assumed from it. Compounded preparations are not FDA-approved and have not been independently studied in the same way.

When should a side effect trigger a call to the prescriber?

Severe abdominal pain, persistent vomiting, signs of dehydration, jaundice, or vision changes are reasons to contact the prescribing clinician promptly. Most GI side effects are dose-related and improve with adjustment.

Do side effects predict effectiveness?

No. There is no reliable evidence that nausea or other GI side effects predict greater weight loss. Trial data show meaningful weight loss in patients with minimal side effects as well as those with more pronounced symptoms.

Can semaglutide help with fatty liver disease?

Wegovy injection now has an indication for a defined noncirrhotic MASH population, as described above. That does not establish the same indication for Ozempic or compounded preparations, or for everyone with liver fat. Patients with existing fatty liver disease should discuss the potential benefits and risks with their prescriber.

Should I get liver labs before starting semaglutide?

Baseline liver enzymes are commonly checked before initiating therapy and during ongoing care, depending on clinical profile. This is standard practice, not a red flag.

Is fatty liver a contraindication to starting semaglutide?

Fatty liver alone is generally not a contraindication. Active liver disease, particularly cirrhosis or severe hepatic impairment, warrants specific clinical evaluation before starting GLP-1 therapy.

How long does it take to see liver enzyme improvement?

This varies by individual. Some patients see normalization within a few months of therapy; others take longer. The trajectory typically tracks with weight loss but may also reflect direct metabolic effects of the medication.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.